Clinical Trials

813 enrolled 16 charts 1 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT03164616 2026-03-13

POSEIDON

1,186 enrolled 26 charts 1 FDA

Non Small Cell Lung Cancer NSCLC

NCT05091567 2026-03-10

IMforte

660 enrolled 23 charts 1 FDA

Small Cell Lung Carcinoma

NCT03036098 2026-03-06

CheckMate901

1,314 enrolled 23 charts 1 FDA

Genitourinary

Urothelial Cancer

NCT04538664 2026-02-25

PAPILLON

308 enrolled 12 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03088540 2026-02-23

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

712 enrolled 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04988295 2026-02-05

MARIPOSA-2

776 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03635567 2026-02-04

KEYNOTE-826

617 enrolled 29 charts 1 FDA

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT02998528 2026-01-06

CheckMate 816

505 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04269200 2025-12-23

DUO-E

805 enrolled 18 charts 1 FDA

Gynecologic

Endometrial Neoplasms

NCT03215706 2025-12-17

CheckMate 9LA

719 enrolled 21 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT01358877 2025-11-28

APHINITY

4,804 enrolled 45 charts 1 FDA

Breast

Breast Neoplasms

NCT02477826 2025-10-30

CheckMate 227

2,747 enrolled 21 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03043872 2025-10-21

CASPIAN

987 enrolled 42 charts 2 FDA

Small Cell Lung Carcinoma

NCT04025879 2025-10-16

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

461 enrolled 18 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04035486 2025-10-10

FLAURA2

587 enrolled 44 charts 1 FDA

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05722015 2025-09-11

MK-3475A-D77

377 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03981796 2025-09-03

RUBY

785 enrolled 2 FDA

Neoplasms, Recurrence

NCT02358031 2025-07-18

MK-3475-048

882 enrolled 50 charts 1 FDA

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Head and Neck Neoplasms

NCT04223856 2025-06-13

EV-302

886 enrolled 12 charts 1 FDA

Genitourinary

Urothelial Cancer

NCT03800134 2025-06-11

AEGEAN

825 enrolled 1 FDA

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT04974398 2025-04-13

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

296 enrolled 1 FDA

Head & Neck

Nasopharyngeal Carcinoma

NCT01828099 2025-01-16

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

376 enrolled 34 charts 1 FDA

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02819518 2024-11-27

KEYNOTE-355

882 enrolled 41 charts 2 FDA

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT02775435 2024-10-08

KEYNOTE-407

559 enrolled 18 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02578680 2024-09-20

MK-3475-189

616 enrolled 19 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02899299 2024-05-21

CheckMate743

605 enrolled 17 charts 2 FDA

Other solid neoplasmThoracic

Mesothelioma

NCT02220894 2023-10-10

Keynote 042

1,274 enrolled 23 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02763579 2023-07-28

IMpower133

503 enrolled 23 charts 1 FDA

Small Cell Lung Carcinoma

NCT02409342 2023-03-15

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

572 enrolled 32 charts 2 FDA

Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

NCT02367781 2021-08-09

IMpower130

723 enrolled 28 charts 1 FDA

Tumor-Agnostic

Carcinoma

NCT00262847 2019-07-23

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer